Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats.

This study was designed to determine the effects of glucagon-like peptides (GLP) on arterial blood pressure and heart rate. Although glucagon caused a minimal effect and GLP-1-(1-37) produced a moderate increase of both systolic and diastolic blood pressure, GLP-1-(7-36) amide induced the greatest increases in both parameters. Systolic and diastolic blood pressure and heart rate values increased when doses of the peptides were increased. By contrast, GLP-2 did not modify either arterial blood pressure or heart rate values. To determine whether the effects of GLP-1-(7-36) amide were mediated through catecholamines, the rats were pretreated with reserpine, propranolol, or phentolamine before administration of the peptide. In these three experimental groups, GLP-1-(7-36) amide increases mean arterial blood pressure and heart rate to the same level or even greater than that observed in nonpretreated rats. These findings indicate that GLP-1-(7-36) amide significantly increases arterial blood pressure and heart rate and that these effects are not mediated through catecholamines.

[1]  F. Mora,et al.  Selective release of glutamine and glutamic acid produced by perfusion of GLP-1(7–36) amide in the basal ganglia of the conscious rat , 1992, Brain Research Bulletin.

[2]  E. Blázquez,et al.  Autoradiographic localization of receptors for glucagon-like peptide-1(7–36) amide in rat brain , 1992, Neuropeptides.

[3]  I. Valverde,et al.  Lipolytic action of glucagon-like peptides in isolated rat adipocytes , 1992, Peptides.

[4]  B. Göke,et al.  Characterization of glucagon‐like peptide‐I(7–36)amide receptors of rat lung membranes by covalent cross‐linking , 1991, FEBS letters.

[5]  J. Holst,et al.  Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. , 1991, The Journal of clinical investigation.

[6]  J. López-Novoa,et al.  Renal catabolism of human glucagon-like peptides 1 and 2. , 1990, Canadian journal of physiology and pharmacology.

[7]  E. Blázquez,et al.  Characterization of high‐affinity receptors for truncated glucagon‐like peptide‐1 in rat gastric glands , 1990, FEBS letters.

[8]  J. Dunbar,et al.  Cardiorespiratory response patterns elicited by microinjections of neuropeptide Y in the nucleus tractus solitarius , 1990, Brain Research Bulletin.

[9]  S. Bloom,et al.  Characterization of glucagon-like peptide-1-(7–36)amide in the hypothalamus , 1989, Brain Research.

[10]  S. Kanse,et al.  Identification and characterization of glucagon‐like peptide‐1 7–36 amide‐binding sites in the rat brain and lung , 1988, FEBS letters.

[11]  D. Drucker,et al.  Glucagon gene expression in vertebrate brain. , 1988, The Journal of biological chemistry.

[12]  J. Lauder,et al.  Distribution of glucagonlike peptide I (GLP‐I), glucagon, and glicentin in the rat brain: An immunocytochemical study , 1988, The Journal of comparative neurology.

[13]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[14]  J. Holst,et al.  Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut , 1987, FEBS letters.

[15]  N. Hoosein,et al.  Human glucagon‐like peptides 1 and 2 activate rat brain adenylate cyclase , 1984, FEBS letters.

[16]  R. Elde,et al.  The nucleus tractus solitarii of the cat: A comparison of Golgi impregnated neurons with methionine‐enkephalin‐ and substance P‐immunoreactive neurons , 1983, The Journal of comparative neurology.

[17]  T. Smitherman,et al.  Cardiac dose response relationship for intravenously infused glucagon in normal intact dogs and men. , 1978, American heart journal.

[18]  K. Prasad.  Glucagon-induced changes in the action potential, contraction, and Na+-K+-ATPase of cardiac muscle. , 1975, Cardiovascular research.

[19]  G. Ross.  Regional circulatory effects of pancreatic glucagon , 1970, British journal of pharmacology.

[20]  W. Schenk,et al.  Hemodynamic Responses to Glucagon: An Experimental Study of Central, Visceral and Peripheral Effects , 1970, Annals of surgery.

[21]  W. Parmley,et al.  Cardiovascular effects of glucagon in man. , 1968, The New England journal of medicine.

[22]  W. Parmley,et al.  Glucagon: Its Enhancement of Cardiac Performance in the Cat and Dog and Persistence of its Inotropic Action Despite Beta‐Receptor Blockade with Propranolol , 1968, Circulation research.

[23]  V. Herbert,et al.  Coated charcoal immunoassay of insulin. , 1965, The Journal of clinical endocrinology and metabolism.